指南与共识膀胱癌与上尿路尿路上皮癌

欧洲泌尿外科学会非肌层浸润性膀胱癌(TaT1及原位癌)指南——2024版指南更新摘要

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.
指南 / 共识 · Eur Urol · 2024-08-17

本文为2024年欧洲泌尿外科学会(EAU)非肌层浸润性膀胱癌(NMIBC,TaT1及原位癌)指南更新摘要,通过结构化文献评估(检索Medline、EMBASE和Cochrane图书馆)制定推荐,强调完善诊断、治疗和随访,以及患者风险分层和适当治疗。

要点

  • 推荐对NMIBC患者进行完善诊断、治疗和随访。
  • 强调定义患者风险分层并给予适当治疗。
  • 指南涵盖风险因素、诊断、分类、预后因素、治疗和随访。

核心结论

  • 2024年EAU NMIBC指南为风险因素、诊断、分类、预后因素、治疗和随访提供了见解,旨在有效整合到临床实践中。

研究设计与样本

  • 通过结构化文献评估识别、整理和评价新近相关证据,检索数据库包括Medline、EMBASE和Cochrane图书馆。

主要发现

  • 关键推荐强调对NMIBC患者进行完善诊断、治疗和随访的重要性。
  • 指南强调定义患者风险分层并给予适当治疗的重要性。

关键数值与推荐

  • 推荐基于替代管理策略的理想与不良后果之间的平衡、证据质量(包括估计确定性)以及患者价值观和偏好的性质与变异性确定推荐强度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. METHODS: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gontero P, Birtle A, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol. 2024. PMID: 39155194. doi:10.1016/j.eururo.2024.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。